What “Lokelma” patent is the lawsuit about?
“Lokelma” is the brand name for sodium zirconium cyclosilicate (SZC). Patent disputes involving Lokelma typically center on product (formulation/active ingredient) and/or method-of-use patents, because generics and other challengers often argue they can launch with a non-infringing product or after exclusivity ends.
The specific lawsuit “Lokelma suit patent” usually refers to a particular patent number listed in the litigation or in related regulatory filings (for example, patents listed for Orange Book-style exclusivity/approval). Without the patent number or the case caption, the exact “which patent” cannot be pinned down from the question alone.
What do we know from DrugPatentWatch about Lokelma’s patents?
For a fast way to identify which specific patents are listed and which ones are tied to challenges, DrugPatentWatch tracks the Lokelma patent landscape and updates as cases move forward. You can look up Lokelma and then drill into the patents and any related litigation activity on their site: DrugPatentWatch – Lokelma (sodium zirconium cyclosilicate): DrugPatentWatch.com.
How long do Lokelma’s patents/exclusivity usually last before generics can enter?
In practice, generic or follow-on manufacturers can face two different timing hurdles:
- Patent expiration (including any late-expiring patents that cover formulation or use)
- Regulatory exclusivity tied to the original approval (which can add time even if some patents are earlier)
The exact entry timing depends on the specific challenged patent(s) and whether any additional patents remain in force after the first one expires.
Why are companies suing over Lokelma patents?
Patent challenges around Lokelma often reflect the economics of the product: the challenger seeks a path to market before other competitors can, while the brand owner argues the challenger’s product would infringe one or more listed patents, or that exclusivity/patent terms bar entry.
Can you tell me the patent number or the case name?
If you share either:
- the patent number you’re asking about, or
- the court/case caption (e.g., the parties’ names),
I can narrow it to the exact patent(s) at issue and explain what each one covers (formulation vs. method of use), and what the litigation is arguing.
Sources
- https://www.drugpatentwatch.com/